Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_assertion type Assertion NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_head.
- NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_assertion wasGeneratedBy ECO_0000203 NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_provenance.
- NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_assertion wasDerivedFrom befree-2016 NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_provenance.
- NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_assertion SIO_000772 15857289 NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_provenance.
- NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_assertion evidence source_evidence_literature NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_provenance.
- NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_assertion description "[This assumption has been derived by the successful development of BCR/ABL tyrosine kinase inhibitors in human chronic myeloid leukemia as well as on the activity of antiCD20 monoclonal antibodies in lymphoproliferative disease and of anti HER2 agents in breast tumors overexpressing the targeted antigens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP491839.RAj7JCVJBq3NqUHPsSnB9EWU-XMGlHdfjAgYe00Z7WB74130_provenance.